Robert B. McFadyen
GlaxoSmithKline (United States) · 24 works · 657 citations · h-index 14
Top works
- Disentangling coupling and NOE pathways involving poorly resolved proton signals: HMQC‐TOCSY and HMQC‐NOESY
- Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064
- Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene
- Novel and potent cyclic cyanamide-based cathepsin K inhibitors
- Exploration of the P1 SAR of aldehyde cathepsin K inhibitors
- Exploration of the P2–P3 SAR of aldehyde cathepsin K inhibitors
- アルデヒド系カテプシンK阻害剤のP 1 部位SAR探究
- Diastereoselectivity in the intramolecular cycloaddition reactions of nitrones derived from 5-alkenals and chiral hydroxylamines
- Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064
- Design of small molecule ketoamide-based inhibitors of cathepsin K
- P2–P3 conformationally constrained ketoamide-based inhibitors of cathepsin K
- FXR agonist activity of conformationally constrained analogs of GW 4064
- Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?
- Acyclic cyanamide-based inhibitors of cathepsin K
- A structural screening approach to ketoamide-based inhibitors of cathepsin K
- Acyclic, orally bioavailable ketone-based cathepsin K inhibitors
- Design of Small Molecule Ketoamide‐Based Inhibitors of Cathepsin K.
- Novel and Potent Cyclic Cyanamide‐Based Cathepsin K Inhibitors.
- Cathepsin K complexed with a cyanopyrrolidine inhibitor
- Cathepsin K complexed with a semicarbazone inhibitor